Stockreport

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – [Read more]